ニュース
Not designing with manufacturing in mind—even during early development—is a key reason fledgling biopharma companies fail.
Some of the most widely used methods include a tangential flow filter (TFF). Instead of flowing through a filter, a sample ...
Current setbacks cannot prevent gene-editing companies from advancing closer to “one-and-done” cures and new products.
Innovative delivery techniques, including high-tech nanoparticles and electroporationdevices, may convey more gene therapies into the clinic.
Montreal-based Nomic Bio broadens its proteomics technology to offer a 1,000-plex protein measurement service.
Study in mice shows how a host-elicited factor benefits gut immunological homeostasis by selectively targeting commensal ceramide molecules.
Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing facility will be ...
Although not designed to eliminate experiments, the model, which is intended to accelerate process development, can reduce the number needed.
Results highlight importance of addressing overwork as an occupational health concern, and the need for workplace policies to ...
GEN talked with several contract development and manufacturing organizations (CDMOs) and/or contract research organizations (CROs) about new ways they are addressing AAV manufacturing challenges.
Ring Therapeutics says it has demonstrated the ability to encapsidate nucleic acid payloads through in vitro assembly.
Cell and gene therapies offer potential new therapeutics but are currently constrained by complex and inefficient manufacturing strategies.
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する